Skip to main content
Premium Trial:

Request an Annual Quote

IntegraGen Hires New CEO to Move Firm From Services Shop to Commercial Player

NEW YORK (GenomeWeb News) — French molecular diagnostics company IntegraGen said today it has appointed Bernard Courtieu as CEO to help the firm “accelerate its commercial efforts.”
 
“We are on the brink of emerging from a research and services firm … to a company able to quickly deliver innovative products though our pipeline and fuel further discovery,” Courtieu said.
 
The company, which focuses on diseases such as obesity, autism, diabetes, schizophrenia, and bipolar disorder, is based in Paris and formed a US subsidiary in New York in December 2006. That business is headed by former Roche executive Robert Gottlieb.
 
Courtieu was a vice president at Gemini Consulting, and he has worked as a consultant for a variety of firms. IntegraGen said Courtieu has experience in R&D, industrial operations, supply-chain management, sales and marketing, and information systems.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.